Literature DB >> 19018670

Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.

Phillipe Nyambi1, Sherri Burda, Mateusz Urbanski, Leo Heyndrickx, Wouter Janssens, Guido Vanham, Arthur Nadas.   

Abstract

To design a vaccine that will remain potent against HIV-1, the immunogenic regions in the viral envelope that tend to change as well as those that remain constant over time must be identified. To determine the neutralization profiles of sequential viruses over time and study whether neutralization patterns correlate with sequence evolution, 12 broadly neutralizing plasmas from HIV-1 subtype B-infected individuals were tested for their ability to neutralize sequential primary HIV-1 subtype B viruses from four individuals. Three patterns of neutralization were observed, including a loss of neutralization sensitivity by viruses over time, an increase in neutralization sensitivity by sequential viruses, or a similarity in the sensitivity of sequential viruses to neutralization. Seven to 11 gp160 clones from each sequential virus sample were sequenced and analyzed to identify mutational patterns. Analysis of the envelope sequences of the sequential viruses revealed changes characteristic of the neutralization patterns. Viruses that evolved to become resistant to neutralizing antibodies also evolved with diverse sequences, with most of the changes being due to nonsynonymous mutations occurring in the V1/V2, as well as in the constant regions (C2, C3, C4), the most changes occurring in the C3. Viruses from the patient that evolved to become more sensitive to neutralization exhibited less sequence diversity with fewer nonsynonymous changes that occurred mainly in the V1/V2 region. The V3 region remained constant over time for all the viruses tested. This study demonstrates that as viruses evolve in their host, they either become sensitive or resistant to neutralization by antibodies in heterologous plasma and mutations in different envelope regions account for these changes in their neutralization profiles.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018670      PMCID: PMC2928491          DOI: 10.1089/aid.2008.0154

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  48 in total

1.  The Staden package, 1998.

Authors:  R Staden; K F Beal; J K Bonfield
Journal:  Methods Mol Biol       Date:  2000

2.  Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Xiao-Hong Wang; Sherri Burda; Tetsuya Kimura; Frank A J Konings; Arthur Nádas; Christopher A Anyangwe; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies.

Authors:  Silvia Sánchez-Martínez; Maier Lorizate; Hermann Katinger; Renate Kunert; José L Nieva
Journal:  AIDS Res Hum Retroviruses       Date:  2006-10       Impact factor: 2.205

4.  Biophysical characterization of V3-lipopeptide liposomes influencing HIV-1 infectivity.

Authors:  Apostolos K Rizos; Stavroula Baritaki; Ioannis Tsikalas; David C Doetschman; Demetrios A Spandidos; Elias Krambovitis
Journal:  Biochem Biophys Res Commun       Date:  2007-02-21       Impact factor: 3.575

5.  Structural basis for coreceptor selectivity by the HIV type 1 V3 loop.

Authors:  Timothy Cardozo; Tetsuya Kimura; Sean Philpott; Barbara Weiser; Harold Burger; Susan Zolla-Pazner
Journal:  AIDS Res Hum Retroviruses       Date:  2007-03       Impact factor: 2.205

6.  Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.

Authors:  C P Krachmarov; W J Honnen; S C Kayman; M K Gorny; S Zolla-Pazner; Abraham Pinter
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.

Authors:  M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo.

Authors:  Stefan Pöhlmann; Jan Münch; Sheriff Aziz; Jacqueline D Reeves; Claas Otto; George J Leslie; Heike Hofmann; Bridget A Puffer; Frédéric Baribaud; Andrea Marzi; Thomas Gramberg; Zhiwei Chen; Nicole Stolte; Peter Ten Haaft; Jonathan L Heeney; Christiane Stahl-Hennig; Kerstin Mätz-Rensing; Thomas Schneider; Robert W Doms; Frank Kirchhoff
Journal:  Virology       Date:  2006-11-28       Impact factor: 3.616

9.  Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.

Authors:  W J Honnen; C Krachmarov; S C Kayman; M K Gorny; S Zolla-Pazner; A Pinter
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

10.  Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120.

Authors:  S Gnanakaran; Dorothy Lang; Marcus Daniels; Tanmoy Bhattacharya; Cynthia A Derdeyn; Bette Korber
Journal:  J Virol       Date:  2006-12-13       Impact factor: 5.103

View more
  5 in total

1.  HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

Authors:  Susan M Schader; Susan P Colby-Germinario; Peter K Quashie; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Thibault Mespléde; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

2.  Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.

Authors:  M Anthony Moody; Feng Gao; Thaddeus C Gurley; Joshua D Amos; Amit Kumar; Bhavna Hora; Dawn J Marshall; John F Whitesides; Shi-Mao Xia; Robert Parks; Krissey E Lloyd; Kwan-Ki Hwang; Xiaozhi Lu; Mattia Bonsignori; Andrés Finzi; Nathan A Vandergrift; S Munir Alam; Guido Ferrari; Xiaoying Shen; Georgia D Tomaras; Gift Kamanga; Myron S Cohen; Noel E Sam; Saidi Kapiga; Elin S Gray; Nancy L Tumba; Lynn Morris; Susan Zolla-Pazner; Miroslaw K Gorny; John R Mascola; Beatrice H Hahn; George M Shaw; Joseph G Sodroski; Hua-Xin Liao; David C Montefiori; Peter T Hraber; Bette T Korber; Barton F Haynes
Journal:  Cell Host Microbe       Date:  2015-09-09       Impact factor: 21.023

3.  Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.

Authors:  Maxim Totrov; Xunqing Jiang; Xiang-Peng Kong; Sandra Cohen; Chavdar Krachmarov; Aidy Salomon; Constance Williams; Michael S Seaman; Ruben Abagyan; Timothy Cardozo; Miroslaw K Gorny; Shixia Wang; Shan Lu; Abraham Pinter; Susan Zolla-Pazner
Journal:  Virology       Date:  2010-07-21       Impact factor: 3.616

4.  Neutralizing Antibody Responses and Evolution of the Viral Envelope in the Course of HIV-1 Korean Clade B Infection.

Authors:  Bo Gyeong Shin; Mi-Ran Yun; Sung Soon Kim; Gab Jung Kim
Journal:  Osong Public Health Res Perspect       Date:  2011-12

5.  Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.

Authors:  Bijayesh Haldar; Sherri Burda; Constance Williams; Leo Heyndrickx; Guido Vanham; Miroslaw K Gorny; Phillipe Nyambi
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.